228 related articles for article (PubMed ID: 17725102)
1. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.
Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G
J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
4. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies.
Inohara H; Segawa T; Miyauchi A; Yoshii T; Nakahara S; Raz A; Maeda M; Miyoshi E; Kinoshita N; Yoshida H; Furukawa M; Takenaka Y; Takamura Y; Ito Y; Taniguchi N
Biochem Biophys Res Commun; 2008 Nov; 376(3):605-10. PubMed ID: 18809382
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules.
Aratake Y; Umeki K; Kiyoyama K; Hinoura Y; Sato S; Ohno A; Kuribayashi T; Hirai K; Nabeshima K; Kotani T
Diagn Cytopathol; 2002 Jun; 26(6):366-72. PubMed ID: 12112826
[TBL] [Abstract][Full Text] [Related]
8. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
9. Can cytomorphology differentiate between benign nodules and tumors arising in Graves' disease?
Anderson SR; Mandel S; LiVolsi VA; Gupta PK; Baloch ZW
Diagn Cytopathol; 2004 Jul; 31(1):64-7. PubMed ID: 15236269
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
11. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
[TBL] [Abstract][Full Text] [Related]
12. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
[TBL] [Abstract][Full Text] [Related]
16. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 immunodetection may improve cytological diagnosis of occult papillary thyroid carcinoma.
Pisani T; Vecchione A; Giovagnolii MR
Anticancer Res; 2004; 24(2C):1111-2. PubMed ID: 15154632
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies.
Rossi ED; Raffaelli M; Minimo C; Mule A; Lombardi CP; Vecchio FM; Fadda G
Cancer; 2005 Apr; 105(2):87-95. PubMed ID: 15742329
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
